Regeneron Pharmaceuticals

REGNNASDAQ

VelociSuite antibody discovery and genetics-enabled target selection

Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-04-09. Published by ClinicalInvestor. Educational analysis only. Read the editorial policy and disclosures.

Filing figures as of June 30, 2026 · text updated 2026-04-09, 222 days ago · archived: kept for reference, not maintained · where each field comes from

Key figures from SEC filings

REGN filings on EDGAR →

Cash & investments

$17.82B

at June 30, 2026 (10-Q)

Quarterly operating burn

No burn

operating cash flow positive, Jan–Jun 2026

Cash runway

—

not a runway: funded by operations

Shares outstanding

94.0M

cover page of the latest filing

Read from REGN's XBRL financial data; latest filing July 30, 2026; fetched 2026-09-28. Runway assumes the reported burn continues unchanged; burn usually rises as programs advance, so treat it as an upper bound. Revenue stage: Commercial.

Upcoming catalysts

Company-specific dates below are registry milestones or filings we have linked. For FDA decision dates site-wide, see the PDUFA calendar.

OLYMPIA-1: Odronextamab in Previously untreated follicular lymphoma — primary completion

2028-02-07

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneSignificant

Pozelimab + cemdisiran PNH: Pozelimab and cemdisiran in Paroxysmal nocturnal haemoglobinuria — primary completion

2030-01-18

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneSignificant

Dupilumab paediatric EoE: Dupilumab in Eosinophilic oesophagitis in children — primary completion

2028-06-19

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneSignificant

Pipeline

DrugIndicationPhaseExpected data
Dupixentmultiple type 2 inflammatory diseasesApprovedNot disclosed▼
Linvoseltamabmultiple myelomaNDA/BLA FiledNot disclosed▼
OdronextamabB-cell lymphomasPhase 3Not disclosed▼

Analysis

We have not yet written an analysis of Regeneron Pharmaceuticals that is specific and current enough to publish. Earlier text here was removed rather than left up: on most profiles it was a template shared with other companies, and where a correction is listed above, it was written before the facts changed. The filing figures, pipeline and sourced catalysts on this page are current; the written thesis will be added from them.
Trade REGN commission-free on Webullvia Webull · Affiliate

Comparable companies

AmgenSanofiVertex Pharmaceuticals

Sponsored

Get premium REGN analysis on Seeking Alpha

Affiliate link — we may earn a commission at no cost to you

Disclaimer: This page is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Clinical trial analysis reflects publicly available data and AI-generated interpretations. Biotech investing carries significant risk including potential total loss of investment. Always verify critical claims through primary sources and consult a qualified financial advisor. Some links on this page are affiliate links. Review our editorial policy and disclosures.

Sponsor's late-stage trial record

Regeneron Pharmaceuticals has 227 Phase 2 or 3 studies on ClinicalTrials.gov: 102 completed, 39 stopped early, 86 ongoing.

102

Completed

39

Stopped early

86

Ongoing

Stopped early

  • LINKER-MM8Phase 2/3 · started 2026 · withdrawn

    Linvoseltamab in multiple myeloma (mm) · n=0

    Reason given: Sponsor Decision

  • NCT07309432Phase 3 · started 2026 · terminated

    REGN5713 in allergic conjunctivitis · n=24

    Reason given: Sponsor Decision

  • TITANPhase 1/2 · started 2025 · terminated

    REGN7041 in active noninfectious uveitis affecting the posterior segment · n=1

    Reason given: Unfavorable benefit-risk assessment

  • NATRIX-SBPPhase 2 · started 2025 · terminated

    REGN5381 in uncontrolled hypertension · n=34

    Reason given: Sponsor decision

  • NCT06384820Phase 2 · started 2024 · withdrawn

    cemiplimab in cutaneous squamous cell carcinoma · n=0

    Reason given: Business Decision

  • NATRIX-BNPPhase 2 · started 2024 · terminated

    REGN5381 in heart failure · n=89

    Reason given: Sponsor decision

  • ACCESS 2Phase 3 · started 2022 · terminated

    Cemdisiran in paroxysmal nocturnal hemoglobinuria · n=3

    Reason given: Sponsor decision not related to efficacy or safety.

  • LEAPPhase 2 · started 2022 · terminated

    REGN4461 in familial partial lipodystrophy · n=20

    Reason given: Sponsor Decision

  • NCT04916002Phase 2 · started 2021 · terminated

    vidutolimod in merkel cell carcinoma · n=77

    Reason given: Sponsor Decision related to study drug supply

  • NCT05081388Phase 1/2 · started 2021 · terminated

    REGN14256 in sars-cov-2 · n=25

    Reason given: Sponsor Decision

  • NCT05074433Phase 3 · started 2021 · terminated

    casirivimab+imdevimab in immunocompromised · n=66

    Reason given: Emerging SARS-CoV2 variants impacting susceptibility to study drug

  • NCT04577820Phase 3 · started 2021 · withdrawn

    garetosmab in fibrodyplasia ossificans progressiva (fop) · n=0

    Reason given: Phase 2 Study R2477-FOP-1940 has been withdrawn and the next phase of the development program is being planned

  • NCT04992273Phase 2 · started 2021 · terminated

    casirivimab+imdevimab in covid-19 · n=7

    Reason given: Emerging SARS-CoV-2 variants impacting susceptibility to study drug

  • NCT04981717Phase 3 · started 2021 · terminated

    REGN1908-1909 in allergic rhinitis due to cat allergy · n=446

    Reason given: Lack of efficacy

  • NCT04863014Phase 2 · started 2021 · terminated

    evinacumab in hypertriglyceridemia · n=21

    Reason given: Sponsor Decision

  • NCT04698187Phase 2 · started 2021 · terminated

    CMP-001 in melanoma · n=44

    Reason given: Business Decision

  • NCT04695977Phase 2/3 · started 2021 · terminated

    CMP-001 in melanoma · n=20

    Reason given: Business Decision

  • NCT04633278Phase 2 · started 2021 · terminated

    CMP-001 in squamous cell carcinoma of head and neck · n=24

    Reason given: Business Decision

  • NCT04373083Phase 2 · started 2020 · withdrawn

    Cemiplimab in hodgkin lymphoma · n=0

    Reason given: Business Decision

  • NCT04425629Phase 3 · started 2020 · terminated

    casirivimab+imdevimab combination therapy in covid-19 · n=10078

    Reason given: Emerging SARS-CoV-2 variants impacting susceptibility to study drug

  • NCT04162470Phase 3 · started 2019 · terminated

    REGN3918 in paroxysmal nocturnal hemoglobinuria · n=24

    Reason given: Business Decision

  • NCT03956550Phase 2 · started 2019 · terminated

    REGN5069 in osteoarthritis of the knee · n=259

    Reason given: Regeneron has discontinued further clinical development of REGN5069, an antibody to GFRα3, which was previously being studied in osteoarthritis pain of the knee

  • NCT03949673Phase 2 · started 2019 · terminated

    Fasinumab in osteoarthritis, knee · n=23

    Reason given: Lack of enrollment

  • NCT03710941Phase 2 · started 2019 · withdrawn

    REGN2477+REGN1033 in sporadic inclusion body myositis · n=0

    Reason given: The study was withdrawn due to an internal decision

  • NCT03738423Phase 2 · started 2018 · terminated

    REGN3500 in atopic dermatitis · n=129

    Reason given: Lack of efficacy

  • NCT03736967Phase 2 · started 2018 · terminated

    REGN3500 in atopic dermatitis · n=206

    Reason given: Lack of efficacy

  • NCT03690869Phase 1/2 · started 2018 · terminated

    cemiplimab (monotherapy) in relapsed solid tumor · n=57

    Reason given: Sponsor Decision

  • NCT03515629Phase 3 · started 2018 · terminated

    REGN2810/ipi in non-small cell lung cancer · n=5

    Reason given: Business decision

  • NCT03430063Phase 2 · started 2018 · terminated

    SDREGN2810 in advanced non-small cell lung carcinoma · n=28

    Reason given: Business decision

  • FACT CLBP 1Phase 3 · started 2017 · terminated

    Fasinumab in chronic low back pain · n=63

    Reason given: Due to implementation of an urgent safety measure, enrollment and dosing in R475-PN-1612 was stopped; enrolled participants entered the 20-week safety follow-up

  • CAPELLAPhase 2 · started 2015 · terminated

    REGN2176-3 in neovascular age-related macular degeneration · n=505

    Reason given: No additional efficacy seen with REGN2176-3 over aflibercept alone

  • NCT01605708Phase 1/2 · started 2012 · terminated

    REGN846 in pruritus · n=19

    No reason recorded in the registry.

  • UPSURGEPhase 3 · started 2011 · terminated

    Rilonacept in gout · n=220

    No reason recorded in the registry.

  • NCT01001923Phase 2 · started 2009 · terminated

    REGN475/SAR164877 in abdominal pain upper · n=15

    Reason given: Business decision due to low subject recruitment and enrollment

  • NCT01001715Phase 2 · started 2009 · terminated

    REGN475/SAR164877 in back pain · n=41

    Reason given: Business decision due to low subject recruitment and enrollment

  • NCT00794417Phase 1/2 · started 2008 · terminated

    Aflibercept in advanced carcinoma · n=60

    No reason recorded in the registry.

  • NCT01053702Phase 2 · started — · withdrawn

    R475 in thermal injury pain · n=0

    Reason given: Sponsor decision

  • NCT01239017Phase 2 · started — · withdrawn

    REGN475 in osteoarthritis · n=0

    No reason recorded in the registry.

  • NCT00609544Phase 2 · started — · withdrawn

    Rilonacept in chronic kidney disease · n=0

    Reason given: Unable to enroll patients

Counts cover interventional Phase 2 and Phase 3 studies registered under this sponsor name, retrieved 2026-09-28 from ClinicalTrials.gov API v2. Trials stop for many reasons — futility, safety, enrollment, funding, or a decision to back a different programme — and the registry often does not say which. This is the sponsor's record, not a prediction about any specific readout.